Cargando…
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717203/ https://www.ncbi.nlm.nih.gov/pubmed/33232456 http://dx.doi.org/10.1093/ecco-jcc/jjaa243 |
_version_ | 1783619296648232960 |
---|---|
author | Agrawal, Manasi Brenner, Erica J Zhang, Xian Colombel, Jean-Frederic Kappelman, Michael D Ungaro, Ryan C Gearry, Richard B Kalpan, Gilaad G Kissous-Hunt, Michele Lewis, James D Ng, Siew C Rahier, Jean-Francois Reinisch, Walter Ruemmele, Frank M Steinwurz, Flavio Underwood, Fox E |
author_facet | Agrawal, Manasi Brenner, Erica J Zhang, Xian Colombel, Jean-Frederic Kappelman, Michael D Ungaro, Ryan C Gearry, Richard B Kalpan, Gilaad G Kissous-Hunt, Michele Lewis, James D Ng, Siew C Rahier, Jean-Francois Reinisch, Walter Ruemmele, Frank M Steinwurz, Flavio Underwood, Fox E |
author_sort | Agrawal, Manasi |
collection | PubMed |
description | BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection. RESULTS: Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn’s disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns. CONCLUSIONS: IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes. |
format | Online Article Text |
id | pubmed-7717203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77172032020-12-09 Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry Agrawal, Manasi Brenner, Erica J Zhang, Xian Colombel, Jean-Frederic Kappelman, Michael D Ungaro, Ryan C Gearry, Richard B Kalpan, Gilaad G Kissous-Hunt, Michele Lewis, James D Ng, Siew C Rahier, Jean-Francois Reinisch, Walter Ruemmele, Frank M Steinwurz, Flavio Underwood, Fox E J Crohns Colitis Short Reports BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection. RESULTS: Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn’s disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns. CONCLUSIONS: IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes. Oxford University Press 2020-11-24 /pmc/articles/PMC7717203/ /pubmed/33232456 http://dx.doi.org/10.1093/ecco-jcc/jjaa243 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
spellingShingle | Short Reports Agrawal, Manasi Brenner, Erica J Zhang, Xian Colombel, Jean-Frederic Kappelman, Michael D Ungaro, Ryan C Gearry, Richard B Kalpan, Gilaad G Kissous-Hunt, Michele Lewis, James D Ng, Siew C Rahier, Jean-Francois Reinisch, Walter Ruemmele, Frank M Steinwurz, Flavio Underwood, Fox E Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry |
title | Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry |
title_full | Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry |
title_fullStr | Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry |
title_full_unstemmed | Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry |
title_short | Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry |
title_sort | physician practice patterns in holding inflammatory bowel disease medications due to covid-19, in the secure-ibd registry |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717203/ https://www.ncbi.nlm.nih.gov/pubmed/33232456 http://dx.doi.org/10.1093/ecco-jcc/jjaa243 |
work_keys_str_mv | AT agrawalmanasi physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT brennerericaj physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT zhangxian physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT colombeljeanfrederic physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT kappelmanmichaeld physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT ungaroryanc physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT gearryrichardb physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT kalpangilaadg physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT kissoushuntmichele physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT lewisjamesd physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT ngsiewc physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT rahierjeanfrancois physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT reinischwalter physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT ruemmelefrankm physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT steinwurzflavio physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry AT underwoodfoxe physicianpracticepatternsinholdinginflammatoryboweldiseasemedicationsduetocovid19inthesecureibdregistry |